SBRA Stock Analysis: Sabra Healthcare REIT | NASDAQ
REIT - Healthcare Facilities | NASDAQ, USA | Market Cap: 5.319m USD | 12M Return: 12.5% | US78573L1061 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 40.4M
Qual. Beats: 0
Rev. Trend: 97.1%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Sabra Health Care REIT, Inc. (NASDAQ: SBRA) is a self-administered, self-managed real estate investment trust that owns and invests in healthcare-related real estate across the United States and Canada. The company is headquartered in Tustin, California, was incorporated on May 10, 2010, and trades as a mid-cap stock within the Real Estate sector under the GICS Health Care REITs sub-industry.
As a healthcare-focused REIT, Sabra primarily generates revenue by leasing its properties to operators of skilled nursing facilities, senior housing, and other healthcare assets, typically through long-term triple-net lease agreements. REITs are generally required to distribute a substantial portion of their taxable income to shareholders in the form of dividends, making them a common income-oriented investment vehicle.
- Skilled nursing occupancy recovery drives rent coverage
- Interest rate cuts ease borrowing costs and support dividend
- Senior housing portfolio expansion through HOLZ joint venture
| Net Income: 65.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA -2.09 > 1.0 |
| NWC/Revenue: 41.11% < 20% (prev 18.38%; Δ 22.73% < -1%) |
| CFO/TA 0.07 > 3% & CFO 371.6m > Net Income 65.4m |
| Net Debt (2.43b) to EBITDA (358.9m): 6.78 < 3 |
| Current Ratio: 43.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (252.3m) vs 12m ago 4.71% < -2% |
| Gross Margin: 61.84% > 18% (prev 67.34%; Δ -5.50% > 0.5%) |
| Asset Turnover: 15.86% > 50% (prev 13.76%; Δ 2.10% > 0%) |
| Interest Coverage Ratio: 1.27 > 6 (EBIT TTM 149.5m / Interest Expense TTM 118.2m) |
| A: 0.06 (Total Current Assets 361.7m - Total Current Liabilities 8.28m) / Total Assets 5.51b |
| B: -0.39 (Retained Earnings -2.15b / Total Assets 5.51b) |
| C: 0.03 (EBIT TTM 149.5m / Avg Total Assets 5.42b) |
| D: 1.00 (Book Value of Equity 2.75b / Total Liabilities 2.76b) |
| Altman-Z'' = 0.38 = B |
As of September 02, 2026, the stock is trading at USD 20.94 with a total of 2,175,163 shares traded. Over the past week, the price has changed by -0.39%, over one month by -2.23%, over three months by +8.65% and over the past year by +12.46%.
Current recommended Stop Loss: 20.20 (which is 3.5% or 1.6 ATR below the current price).
Sabra Healthcare REIT has received a consensus analysts rating of 3.85. Therefore, it is recommended to buy SBRA.
- StrongBuy: 5
- Buy: 1
- Hold: 7
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 22.6 | 7.8% |
P/E Trailing = 80.0769
P/E Forward = 32.1543
P/S = 6.1576
P/B = 1.9011
P/EG = 5.2841
Revenue TTM = 859.6m USD
EBIT TTM = 149.5m USD
EBITDA TTM = 358.9m USD
Long Term Debt = 2.31b USD (from longTermDebt, last quarter)
Short Term Debt = 1.08m USD (from shortTermDebt, last quarter)
Debt = 2.66b USD (from shortLongTermDebtTotal, last quarter) + Leases 19.1m
Net Debt = 2.43b USD (calculated: Debt 2.66b - CCE 231.6m)
Enterprise Value = 7.75b USD (5.32b + Debt 2.66b - CCE 231.6m)
Interest Coverage Ratio = 1.27 (Ebit TTM 149.5m / Interest Expense TTM 118.2m)
EV/FCF = 29.52x (Enterprise Value 7.75b / FCF TTM 262.6m)
FCF Yield = 3.39% (FCF TTM 262.6m / Enterprise Value 7.75b)
FCF Margin = 30.55% (FCF TTM 262.6m / Revenue TTM 859.6m)
Net Margin = 7.61% (Net Income TTM 65.4m / Revenue TTM 859.6m)
Gross Margin = 61.84% ((Revenue TTM 859.6m - Cost of Revenue TTM 328.0m) / Revenue TTM)
Gross Margin QoQ = 60.88% (prev 61.38%)
Tobins Q-Ratio = 1.41 (Enterprise Value 7.75b / Total Assets 5.51b)
Interest Expense / Debt = 4.43% (Interest Expense 118.2m / Debt 2.66b)
Taxrate = 3.37% (2.13m / 63.2m)
NOPAT = 144.4m (EBIT 149.5m * (1 - 3.37%))
Current Ratio = 4.46 (Total Current Assets 361.7m / Total Current Liabilities 81.1m)
Debt / Equity = 0.97 (Debt 2.66b / totalStockholderEquity, last quarter 2.75b)
Debt / EBITDA = 6.78 (Net Debt 2.43b / EBITDA 358.9m)
Debt / FCF = 9.26 (Net Debt 2.43b / FCF TTM 262.6m)
Total Stockholder Equity = 2.80b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.21% (Net Income 65.4m / Total Assets 5.51b)
RoE = 2.34% (Net Income TTM 65.4m / Total Stockholder Equity 2.80b)
RoCE = 2.93% (EBIT 149.5m / Capital Employed (Equity 2.80b + L.T.Debt 2.31b))
RoIC = 2.64% (NOPAT 144.4m / Invested Capital 5.46b)
WACC = 4.76% (E(5.32b)/V(7.98b) * Re(5.0%) + D(2.66b)/V(7.98b) * Rd(4.43%) * (1-Tc(0.03)))
Discount Rate = 5.0% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.71 | Cagr: 3.52%
[DCF] Terminal Value 73.10% ; FCFF base≈303.5m ; Y1≈266.2m ; Y5≈215.1m
[DCF] Fair Price = 3.99 (EV 3.45b - Net Debt 2.43b = Equity 1.02b / Shares 255.5m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.52 | # QB: 0
Revenue Correlation: 97.14 | Revenue CAGR: 12.88% | SUE: 2.26 | # QB: 1
EPS current Quarter (2026-09-30): EPS=0.17 | Chg30d=-1.94% | Revisions=-25% | Analysts=3
EPS current Year (2026-12-31): EPS=0.67 | Chg30d=+0.00% | Revisions=-25% | GrowthEPS=+11.0% | GrowthRev=+19.0%
EPS next Year (2027-12-31): EPS=0.78 | Chg30d=+4.49% | Revisions=+25% | GrowthEPS=+15.9% | GrowthRev=+8.9%
[Analyst] Revisions Ratio: -17% (up=1, down=2)